calcifediol

Ligand id: 6921

Name: calcifediol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: calcidiol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 40.46
Molecular weight 400.33
XLogP 7.93
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
25-hydroxyvitamin D3 is effective in the treatment of rickets and osteomalacia. The US FDA originally approved this nutraceutical in 1980, but use was discontinued.
In June 2016, the FDA approved the Rayaldee® extended release formulation of calcifediol as the first treatment for patients with hyperparathyroidism secondary to chronic kidney disease (e.g. predialysis patients). Rayaldee® is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.
Mechanism Of Action and Pharmacodynamic Effects
Activates the transcriptional activity of the vitamin D receptor which eventually leads to increased serum calcium levels.